Fortress Biotech (FBIO) Accounts Payables (2010 - 2026)

Fortress Biotech's Accounts Payables history runs 16 years deep, the most recent figure standing at $47.1 million for Q4 2025.

• In Q4 2025, Accounts Payables fell 28.05% year-over-year to $47.1 million; the TTM figure through Dec 2025 stood at $47.1 million (down 28.05% YoY), while the FY2025 annual figure was $47.1 million, down 28.05% from the prior year.
• Accounts Payables for Q4 2025 stood at $47.1 million, up from $45.2 million in the prior quarter.
• The five-year high for Accounts Payables was $105.4 million in Q1 2023, with the low at $39.2 million in Q1 2021.
• The 5-year median for Accounts Payables is $75.0 million (2023), against an average of $74.5 million.
• The sharpest annual moves came in 2021 and 2024: Accounts Payables surged 154.61% in 2021, then tumbled 30.5% in 2024.
• Fortress Biotech's Accounts Payables stood at $90.7 million in 2021, then increased by 7.49% to $97.4 million in 2022, then fell by 24.51% to $73.6 million in 2023, then slipped by 10.96% to $65.5 million in 2024, then dropped by 28.05% to $47.1 million in 2025.
• Business Quant data shows FBIO's Accounts Payables at $47.1 million in Q4 2025, $45.2 million in Q3 2025, and $48.6 million in Q2 2025.